NetEase to Report First Quarter 2025 Financial Results on May 15
HANGZHOU, China, April 30, 2025 /PRNewswire/ — NetEase, Inc. (NASDAQ: NTES and HKEX: 9999, “NetEase” or the “Company”), a leading... Read more.
Rivada Expands Middle East Team
Rivada’s Outernet offers unique low-latency, highly secure connectivity for enterprise & government High-speed global data constellation using satellite-to-satellite... Read more.
Finastra launches Transformation Service to support multiple messaging standards, including ISO 20022
Seamless message format translation embedded as a microservice within the Finastra Financial Messaging platform, with value-added overlay services for Swift CBPR+... Read more.
Castlelake and TradeBridge Agree Additional £70m Financing Facility
MINNEAPOLIS and LONDON, April 30, 2025 /PRNewswire/ — Castlelake, L.P. (“Castlelake”), a global alternative investment manager specializing in... Read more.
Yealink Launches MeetingBoard Pro to Elevate Meeting Equity and Team Collaboration
XIAMEN, China, April 30, 2025 /PRNewswire/ — Two years after Yealink launched MeetingBoard, this innovative all-in-one videoconferencing board, certified... Read more.
WirelessCar Showcases the Future of Connected Mobility at World Expo 2025 Osaka and AEE Yokohama
GOTHENBURG, Sweden, April 30, 2025 /PRNewswire/ — WirelessCar, a global leader in connected vehicle services, will take center stage at World Expo 2025 Osaka... Read more.
Silicon Motion Announces Results for the Period Ended March 31, 2025
Business Highlights First quarter of 2025 sales decreased 13% Q/Q and decreased 12% Y/Y SSD controller sales: 1Q of 2025 decreased 10% to 15% Q/Q and decreased 20% to 25% Y/Y... Read more.
Waterdrop Inc. Releases 2024 Annual Report: AI-Enabled Efficiencies Drive Business Growth
BEIJING, April 30, 2025 /PRNewswire/ — Waterdrop Inc. (“Waterdrop”, the “Company” or “we”) (NYSE: WDH), a leading technology... Read more.
Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025
Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors... Read more.
Uxin Reports Unaudited Financial Results for the Quarter and Full Year Ended December 31, 2024
BEIJING, April 30, 2025 /PRNewswire/ — Uxin Limited (“Uxin” or the “Company”) (Nasdaq: UXIN), China’s leading used car retailer,... Read more.